In melanoma patients, NLR strongly predicted poorer response in patients treated with ICI, and high CD14+, CD16+, and HLA-DRhi cell levels predicted response to anti-PD-1 therapy [128, 129]. The gene discussed is PDCD1; the disease is melanoma.